Go Ad-Free
    My Alerts
    VICTORIS
    Budget Express 2026

    co-presented by

    • LIC
    • JIO BlackRock

    ASSOCIATE SPONSORS

    • Sunteck
    • SBI
    • Emirates
    • Dezerv
    HomeNewsBusinessAnnouncementsUnichem Lab gets ANDA approval from USFDA for Amlodipine Besylate Tablets

    Unichem Lab gets ANDA approval from USFDA for Amlodipine Besylate Tablets

    Unichem laboratories has received ANDA approval from the United States Food and Drug Administration (USFDA) for Amlodipine Besylate Tablets. Amlodipine Besylate Tablets USP 2.5mg, 5mg and 10mg are therapeutically equivalent to NORVASC Tablets 2.5mg, 5mg and 10mg from Pfizer Inc.

    October 25, 2013 / 09:30 IST

    Unichem Laboratories Ltd has informed BSE regarding a Press Release dated October 24, 2013, titled "Unichem Laboratories receives ANDA approval from USFDA for Amlodipine Besylate Tablets" Unichem laboratories has received ANDA approval from the United States Food and Drug Administration (USFDA) for Amlodipine Besylate Tablets. Amlodipine Besylate Tablets USP 2.5mg, 5mg and 10mg are therapeutically equivalent to NORVASC Tablets 2.5mg, 5mg and 10mg from Pfizer Inc. Amlodipine Besylate Tablet USP is a calcium channel blocker indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.Source : BSE

    Read all announcements in Unichem Labs

    Read More Read More

    first published: Oct 25, 2013 09:30 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347